Mortality trends in polymyositis and dermatomyositis: A general population-based study

被引:7
作者
Li, Lingyi [1 ,2 ]
D'Silva, Kristin M. [3 ]
Lu, Na [2 ]
Huang, Kun [4 ]
Esdaile, John M. [1 ,2 ,4 ]
Choi, Hyon K. [2 ,3 ]
Avina-Zubieta, J. Antonio [1 ,2 ,4 ]
机构
[1] Univ British Columbia, Dept Med, Expt Med Program, Vancouver, BC, Canada
[2] Arthrit Res Canada, Richmond, BC, Canada
[3] Harvard Med Sch, Massachusetts Gen Hosp, Div Rheumatol Allergy & Immunol, Boston, MA 02115 USA
[4] Univ British Columbia, Dept Med, Div Rheumatol, Vancouver, BC, Canada
基金
加拿大健康研究院; 美国国家卫生研究院;
关键词
Polymyositis; Dermatomyositis; Mortality; Population-based; Cohort; ADMINISTRATIVE DATA; CANCER-RISK; DECLINE;
D O I
10.1016/j.semarthrit.2020.08.009
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objective: To evaluate mortality trends in polymyositis (PM) and dermatomyositis (DM) between January 1, 1997, and December 31, 2014. Methods: Using an administrative health database from the province of British Columbia, Canada, we identified all patients with incident PM/DM and up to 10 age-, sex-, and index date matched non-PM/DM individuals. Study cohorts for both PM and DM were divided into two subgroups based on the year of diagnosis (i.e., early cohort [1997-2005] and late cohort [2006-2014]). Mortality rates, hazard ratios (HRs), and rate differences were compared between these cohorts. Results: Mortality rates (per 1000 person-years) in the early cohorts for PM and DM patients were higher than those in the late cohorts (for PM: 58.6 vs. 39.4; for DM: 80.6 vs. 51.3), whereas smaller improvements were observed in the comparison cohorts (for non-PM: 15.5 vs. 12.5; for non-DM: 14.1 vs. 11.5). Corresponding to these two time periods, multivariable HRs for PM were 2.4 (95% CI, 1.7 to 3.4) and 2.0 (95% CI, 1.4 to 2.9), respectively (P-value for interaction=0.62). The corresponding absolute mortality rate differences were 32.6 (95% CI, 20.8 to 44.4) and 18.6 (95% CI, 9.2 to 28.0), respectively (P-value for interaction=0.02). Similar results with higher HRs and risk differences were seen in DM. Conclusions: In this general population study, we found a declining excess mortality in PM or DM patients in recent years, although there was a considerable residual premature mortality gap in the late cohort. (C) 2020 Elsevier Inc. All rights reserved.
引用
收藏
页码:834 / 839
页数:6
相关论文
共 30 条
  • [1] Prognosis and mortality of polymyositis and dermatomyositis patients
    Airio, A
    Kautiainen, H
    Hakala, M
    [J]. CLINICAL RHEUMATOLOGY, 2006, 25 (02) : 234 - 239
  • [2] [Anonymous], 2017, CONS FIL MSP REG PRE
  • [3] [Anonymous], 2017, BC CANC REG DAT
  • [4] BC Ministry of Health, 2018, PHARMANET
  • [5] The Accuracy of Administrative Data Diagnoses of Systemic Autoimmune Rheumatic Diseases
    Bernatsky, Sasha
    Linehan, Tina
    Hanly, John G.
    [J]. JOURNAL OF RHEUMATOLOGY, 2011, 38 (08) : 1612 - 1616
  • [6] Healthcare Costs of Inflammatory Myopathies
    Bernatsky, Sasha
    Panopalis, Pantelis
    Pineau, Christian A.
    Hudson, Marie
    St Pierre, Yvan
    Clarke, Ann E.
    [J]. JOURNAL OF RHEUMATOLOGY, 2011, 38 (05) : 885 - 888
  • [7] British Columbia ministry of health,, 2017, POP DAT BC
  • [8] British Columbia Vital Statistics Agency, 2017, VIT STAT DEATHS POP
  • [9] Canadian Institute of Health Information, 2017, DISCH ABSTR DAT HOSP
  • [10] Risk of deep venous thrombosis and pulmonary embolism in individuals with polymyositis and dermatomyositis: a general population-based study
    Carruthers, Erin C.
    Choi, Hyon K.
    Sayre, Eric C.
    Avina-Zubieta, J. Antonio
    [J]. ANNALS OF THE RHEUMATIC DISEASES, 2016, 75 (01) : 110 - 116